| abstract |
Compounds of formula (I) or salts, N-oxides, hydrates or solvates thereof are inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C 6 alkylene radical. n is 0 or 1. Q represents a radical of formula -(Alk 1 ) p (X) r -(Alk 2 ) s -Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; Alk 1 and Alk 2 are optionally substituted divalent C 1 -C 6 alkylene radicals which may contain a —O—, —S— or —NR A — link, wherein R A is hydrogen or C 1 -C 6 alkyl; X represents —O—, —S—, —(C═O)—, —(C═S)—, —SO 2 —, —SO—, —C(═O)O—, —OC(═O)—, —C(═O)NR A—, —NR A C(═O)—, —C(═S)NR A , —NR A C(═S)—, —SO 2 NR A —, —NR A SO 2 —, —OC(═O)NR A—, —NR A C(═O)O—, or —NR A — wherein R A is hydrogen or C 1 -C 6 alkyl. p, r and s are independently 0 or 1. R 1 represents a radical -(Alk 3 ) a -(Y)b-(Alk 4 ) d -B wherein a, b and d are independently 0 or 1; Alk 3 and Alk 4 are optionally substituted divalent C,-C3 alkylene radicals; Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, —O—, —S—, or —NR A — wherein R A is hydrogen or C 1 -C 6 alkyl; B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is —NR A — and b is 1, then R A and the radical -(Alk 4 ) d -B taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring. R represents hydrogen, halo, C 1 -C 6 alkyl, C1-C 6 alkoxy, C 1 -C 6 alkylthio, phenyl, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms. |